Safety, Tolerability, and Pharmacokinetics of KP-1461 in Phase I Clinical Studies
Background: KP-1461 is a prodrug to KP-1212. KP-1212 is a viral mutagen designed to increase viral error rate. Methods: We describe 2 phase I studies: KP1461-101 (double-blind, placebo-controlled, single, escalating doses, 100 to 1600 mg study in 42 non-HIV-infected participants) and KP-1461-102 (do...
Gardado en:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publishing
2011-08-01
|
| Series: | Journal of the International Association of Providers of AIDS Care |
| Acceso en liña: | https://doi.org/10.1177/1545109711406442 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|